Do you suffer from ulcerative Pyoderma Gangrenosum?
There is a new clinical trial currently open for enrolment of eligible patients to participate.
The study drug, called “vilobelimab”, has a new mode of action to fight your destructive and painful disease. This worldwide Phase III clinical trial, which is conducted in the USA, Australia and several European countries and which is aiming for marketing approval, is based on a successful previous trial conducted by the sponsor InflaRx GmbH. The new trial comprises 18 ambulatory visits with 13 study drug infusions. Using this link you can fill out a questionnaire to see if you might qualify to participate in this clinical trial. You will receive an adequate allowance for your expenses associated with the trial visits.
In case you face any technical issues and need our support, please do not hesitate to contact us.
Application form
